---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-006558"
form_type: "8-K"
ticker: "BAX"
cik: "0000010456"
company_name: "BAXTER INTERNATIONAL INC"
filed_at: "2025-02-20T23:59:59+00:00"
generated_at: "2026-05-26T07:55:13.878187+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Baxter Q4 adj EPS $0.58 beats guidance; Q4 sales $2.75B (+2% CC)

## Summary
- Q4 sales from continuing ops $2.75B, up 1% reported / 2% constant currency, exceeding guidance.
- GAAP diluted EPS loss ($0.95); adjusted EPS $0.58, ahead of company's guidance range.
- Full-year 2024 sales $10.64B (+3% reported & CC); adjusted EPS $1.89, exceeded guidance.
- Sale of Kidney Care business completed, streamlining Baxter for next stage of growth.

## SEC filing metadata
- accession: 0001628280-25-006558
- form_type: 8-K
- ticker: BAX
- cik: 0000010456
- company_name: BAXTER INTERNATIONAL INC
- filed_at: 2025-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10456/000162828025006558/0001628280-25-006558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10456/000162828025006558/bax-20250220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-006558
- JSON: https://secwatch.observer/filing/0001628280-25-006558.json
- Plain text: https://secwatch.observer/filing/0001628280-25-006558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.